| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
DPyPE functions as a co-lipid in lipid-based delivery systems, serving as an auxiliary lipid for the cationic lipid formulation Vaxfectin. It does not have specific pharmacological targets but contributes to the structural integrity and functionality of lipid nanoparticles for gene delivery. The phytanoyl chains provide membrane fluidity and stability to lipid formulations.
|
|---|---|
| ln Vitro |
DPyPE is not evaluated for traditional biological activity, as it is a lipid component used in formulation development rather than a pharmacologically active compound. Its utility is based on its physical and chemical properties as a phospholipid. It is used as a co-lipid in Vaxfectin and other lipid-based delivery systems.
|
| ln Vivo |
DPyPE is not used for in vivo pharmacological evaluation as a therapeutic agent. It is a lipid component used in formulation development for gene delivery and other applications. The compound is incorporated into lipid nanoparticles that are administered to animals for research purposes. However, the lipid itself is not evaluated as a therapeutic agent.
|
| Enzyme Assay |
In vitro assays for DPyPE typically involve evaluation of its physical and chemical properties rather than biological activity. Lipid nanoparticle formulations containing DPyPE are characterized for size, zeta potential, and encapsulation efficiency. The compound's purity is confirmed by HPLC or TLC. Its utility is assessed by the performance of lipid formulations in cell transfection or delivery studies.
|
| Cell Assay |
In vitro cellular assays for DPyPE typically involve evaluation of lipid nanoparticle formulations containing DPyPE for transfection efficiency or delivery of nucleic acids. Cells are treated with lipid nanoparticles containing DPyPE, and delivery of cargo (DNA, mRNA, siRNA) is assessed by reporter gene expression or qPCR. Cytotoxicity is assessed using standard cell viability assays.
|
| Animal Protocol |
In vivo animal experiments for DPyPE typically involve administration of lipid nanoparticle formulations containing DPyPE. The lipid is incorporated into Vaxfectin or other formulations for gene delivery or vaccine applications. Animals are administered the formulations via various routes, and delivery efficiency, biodistribution, and therapeutic efficacy are assessed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of DPyPE are characteristic of phospholipids. The compound has a molecular weight of 776.12 g/mol and a molecular formula of C₄₃H₈₆NO₈P. As a lipophilic phospholipid, it is expected to have limited aqueous solubility and is incorporated into lipid nanoparticles for administration. The compound is stored under appropriate conditions for lipid formulations.
|
| Toxicity/Toxicokinetics |
The toxicological profile of DPyPE is consistent with its use as a lipid component in formulation development. As a phospholipid, it is expected to have relatively low toxicity. Comprehensive toxicological evaluations have not been extensively reported. Standard laboratory safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
DPyPE (CAS# 201036-16-0, molecular formula C₄₃H₈₆NO₈P, molecular weight 776.12) is a phosphatidylethanolamine lipid consisting of polyisoprene alkyl chains. Also known as 1,2-Diphytanoyl-sn-glycero-3-PE. It is the auxiliary lipid of Vaxfectin, mixed with GAP-DMORIE in a 1:1 ratio. Used in lipid-based delivery systems. No clinical trials or regulatory approvals have been identified.
|
| Molecular Formula |
C45H90NO8P
|
|---|---|
| Molecular Weight |
804.17
|
| Exact Mass |
803.64
|
| CAS # |
201036-16-0
|
| PubChem CID |
9963917
|
| Appearance |
Off-white to light yellow ointment
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
774.3±70.0 °C at 760 mmHg
|
| Flash Point |
422.1±35.7 °C
|
| Vapour Pressure |
0.0±5.7 mmHg at 25°C
|
| Index of Refraction |
1.471
|
| LogP |
16.48
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
39
|
| Heavy Atom Count |
55
|
| Complexity |
994
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CC(C)CCCC(C)CCCC(C)CCCC(C)CC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CC(C)CCCC(C)CCCC(C)CCCC(C)C
|
| InChi Key |
XLPHMKQBBCKEFO-DHYROEPTSA-N
|
| InChi Code |
InChI=1S/C45H90NO8P/c1-35(2)17-11-19-37(5)21-13-23-39(7)25-15-27-41(9)31-44(47)51-33-43(34-53-55(49,50)52-30-29-46)54-45(48)32-42(10)28-16-26-40(8)24-14-22-38(6)20-12-18-36(3)4/h35-43H,11-34,46H2,1-10H3,(H,49,50)/t37?,38?,39?,40?,41?,42?,43-/m1/s1
|
| Chemical Name |
[(2R)-3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-(3,7,11,15-tetramethylhexadecanoyloxy)propyl] 3,7,11,15-tetramethylhexadecanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2435 mL | 6.2176 mL | 12.4352 mL | |
| 5 mM | 0.2487 mL | 1.2435 mL | 2.4870 mL | |
| 10 mM | 0.1244 mL | 0.6218 mL | 1.2435 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
